EFFICACY OF OMALIZUMAB IN ASTHMA: CASE REPORT

Abstract

Omalizumab – monoclonal antibody against immunoglobulin E – is used as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. Omalizumab improves asthma control and reduces incidents of exacerbations and doses of steroids. Scientific studies show that this drug is effective as add-on therapy for the treatment of chronic spontaneous urticaria with inadequate response to H1 antihistamine treatment. The aim of this article is to review efficacy of omalizumab for treatment of severe asthma and present case report.